DBV Technologies Reports Full Year 2025 Financial Results and Business Update
Rhea-AI Summary
DBV Technologies (Nasdaq: DBVT) reported full year 2025 results and a business update focused on advancing VIASKIN® Peanut Patch clinical programs for ages 1–7 and preparing for BLA submissions.
Key facts: positive Phase 3 VITESSE topline, 2025 PIPE and ATM financings, $194.2M cash at 12/31/2025 plus $94M received January 2026, and cash runway into Q2 2027.
Positive
- Positive VITESSE topline in Phase 3 for ages 4–7 (Dec 16, 2025)
- $194.2M cash on Dec 31, 2025 plus $94M received Jan 2026, funding into Q2 2027
- 2025 PIPE financing of up to $306.9M to support BLA submission and launch
- Leadership hires added CCO and CHRO to bolster commercialization readiness
Negative
- Net loss widened to $147.0M in 2025 from $113.9M in 2024
- R&D expenses increased by $27.3M to support clinical and pre-commercial activities
- Net cash used in operations was $121.2M in 2025, indicating high burn rate
News Market Reaction – DBVT
On the day this news was published, DBVT declined 1.04%, reflecting a mild negative market reaction. Argus tracked a peak move of +2.0% during that session. Our momentum scanner triggered 6 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $11M from the company's valuation, bringing the market cap to $1.09B at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
DBVT is up 3.68% while close biotech peers show mixed, mostly modest moves (e.g., CAPR +1.73%, CADL -1.12%, NGNE -1.2%), pointing to company-specific drivers rather than a broad sector shift.
Previous Earnings Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Oct 28 | Q3 2025 earnings | Negative | -2.2% | Reported Q3 2025 loss and high operating expenses despite recent financing. |
| Jul 29 | Q2/H1 2025 earnings | Negative | -4.1% | H1 2025 net loss and higher operating expenses with ongoing going concern doubts. |
| Apr 30 | Q1 2025 earnings | Negative | -4.4% | Q1 2025 loss and low cash before PIPE proceeds, highlighting funding needs. |
| Nov 06 | Q3 2024 earnings | Negative | -4.0% | Q3 2024 results with rising expenses, larger losses and limited cash runway. |
| Jul 30 | Q2/H1 2024 earnings | Neutral | +2.3% | Q2 2024 results combining program progress with higher losses and runway concerns. |
Recent earnings releases have typically been followed by modest negative moves, suggesting a cautious market stance around DBVT financial updates.
Over the past two years, DBV’s earnings releases have focused on rising operating expenses, sizable net losses, and constrained cash runways tied to development of the VIASKIN Peanut Patch. Prior updates often highlighted going concern risks and the need for external financing, including a $306.9M PIPE and a $150M ATM program. Market reactions around these earnings prints averaged about a low single‑digit decline, indicating that investors have historically treated financial updates as risk‑focused rather than as positive catalysts.
Historical Comparison
In the last five earnings or annual result updates, DBVT’s stock moved on average -2.49%, reflecting generally cautious reactions to loss‑making financial profiles.
Earnings history shows a shift from short cash runways and substantial going concern doubts toward improved liquidity, supported by large 2025 financings and extended runway tied to the VIASKIN Peanut Patch program.
Market Pulse Summary
This announcement combines full-year 2025 results with a business update highlighting progress toward VIASKIN Peanut Patch commercialization. Key elements include net loss of $147.0M, operating income of $5.6M, cash of $194.2M at year-end 2025, and an additional $94M in January 2026 proceeds, extending runway into Q2 2027. Historically, earnings events averaged a -2.49% move, underscoring how closely investors track liquidity, loss trajectory, and BLA and launch milestones for this late-stage biotech.
Key Terms
biologics license application regulatory
at-the-market (atm) program financial
private placement financing financial
u.s. gaap financial
ifrs financial
research tax credit financial
going concern financial
AI-generated analysis. Not financial advice.
Châtillon, France, March 26, 2026
DBV Technologies Reports Full Year 2025 Financial Results and Business Update
- Continued advancing the VIASKIN® Peanut Patch clinical development programs in peanut-allergic toddlers (1 through 3 years old) and children (4 through 7 years old)
- Bolstered executive leadership team in preparation for BLA submission and potential approval
- Reported cash and cash equivalents of
$194 million as of December 31, 2025, plus additional gross proceeds of$94 million received on January 16, 2026 —providing funding into the second quarter of 2027
DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Capital Market: DBVT) (the “Company”), a late-stage biopharmaceutical company, today reported financial results for the full year 2025. The consolidated financial statements are prepared under U.S. Generally Acceptable Accounting Principles (“U.S. GAAP”) and International Financial Reporting Standards (“IFRS”) for the purpose of Form 10-K and French “Document d’Enregistrement Universel” containing the Annual Financial Report – were approved by the Board of Directors on March 26, 2026.
“We entered 2025 with a clear set of priorities – strengthening our financial position, advancing our clinical development program (including completing VITESSE and initiating COMFORT Toddlers), and preparing for the BLA submission and commercialization of the VIASKIN® Peanut Patch in the United States, if approved,” said Daniel Tassé, Chief Executive Officer of DBV Technologies. “I am pleased with our progress to date in enhancing DBV’s capabilities and building a company ready for launch. Our focus on bringing the VIASKIN® Peanut Patch to peanut-allergic children ages 1-7 years remains unwavering.”
2025 Operational Highlights
Clinical Execution
- Continued to advance clinical program for the VIASKIN® Peanut Patch across both toddlers and children
- Reported positive topline results from the Phase 3 VITESSE trial in peanut-allergic children aged 4 to 7 years
- Initiated supplemental safety study, COMFORT Toddlers, for peanut-allergic toddlers aged 1 to 3 years
- Announced planned clinical study to assess the efficacy and safety of the VIASKIN® Peanut Patch in achieving ad lib consumption of dietary peanut in peanut-allergic infants 6 through 12 months of age following a minimum of 3 years of treatment
Scientific Engagement
- Maintained active engagement with allergy, immunology, and patient advocacy communities through participation in leading scientific and medical congresses, including American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting, the European Academy of Allergy and Clinical Immunology (EAACI) Congress, and the American College of Allergy, Asthma, and Immunology (ACAAI) Annual Scientific Meeting
Leadership Expansion
- Bolstered leadership capabilities in preparation for potential commercialization
- Appointed Kevin Trapp as Chief Commercial Officer and James Briggs as Chief Human Resources Officer to strengthen ability to grow, plan, and execute a launch in the United States, if approved
- Appointed Philina Lee, Ph.D. to Board of Directors (subject to ratification by the Company’s shareholders at the next annual meeting of shareholders), adding deep expertise in biotechnology strategy and commercialization
Financial Position
- Announced a private placement financing (”2025 PIPE”) of up to
$306.9 million (€284.5 million ) on March 27, 2025, to advance the VIASKIN® Peanut Patch through Biologics License Application (”BLA”) submission and U.S. commercial launch, if approved. The 2025 PIPE included gross proceeds of$125.5 million (€116.3 million at the exchange rate of 1 EUR =$1.08) received on April 7, 2025 and$100.7 million as of December 31, 2025 (€85 ,7 million at the exchange rate of 1 EUR =$1.17) resulting from the exercise of the ABSA Warrants and BS Warrants, following the announcement of the positive VITESSE Topline Results on December 16, 2025 - Further strengthened balance sheet through the launch of a
$150 million At-the-Market (ATM) program, subsequently subscribed for$65 million as of December 31, 2025
Anticipated 2026 Events
- BLA Submission for 4-7 year olds anticipated in the first half of 2026 with potential for Priority Review
- Completion of enrollment of COMFORT Toddlers safety study and subsequent topline results readout
- BLA submission for 1-3 year olds anticipated in the second half of 2026 under an Accelerated Approval Pathway
Financial Highlights for the Full Year 2025
2025 Financial Highlights are presented under both U.S. GAAP and IFRS. Comments are provided on a U.S. GAAP basis. Differences between U.S. GAAP and IFRS consolidated financial statements result mainly from the application of lease accounting standards.
Financial Performance
Operating Income
For the year ended December 31, 2025, operating income totaled
Research and Development Expenses
R&D expenses increased by
- Pre-commercial inventory of
$16.1 million , in preparation of the launch of VIASKIN® Peanut Patch for children aged 4 to 7 years old in the U.S., if approved - External clinical expenses of
$6.9 million , with COMFORT Toddlers study ongoing patient enrollment - Employee-related costs of
$3.3 million from the addition of Quality and Regulatory resources to support BLA submission and commercial readiness activities
Selling, General and Administrative Expenses
SG&A Expenses increased by
Net Loss
Net loss was
Cash Position and Liquidity
On December 31, 2025, DBV held
Net cash used for operating activities was
Net cash flows from financing activities totaled
Considering the supplemental gross proceeds received from completed ABSA and BS warrants exercises (
The going concern assessment is based on the Company’s current forecasts and exclude any additional expenditure related to other programs than the VIASKIN® Peanut Patch or resulting from the potential in licensing or acquisition of additional product candidates or technologies, or any associated development the Company may pursue. Assumptions used in the going concern assessment may differ from actual results, and the Company may end up using its resources sooner than anticipated and seek additional resources to execute the corporate strategy either through new or existing financing strategies.
Audited Consolidated Statement of Operations (In millions of USD)
| | US GAAP December 31, | IFRS December 31, | ||
| 2025 | 2024 | 2025 | 2024 | |
| Operating income | 5.6 | 4.2 | 5.6 | 4.2 |
| Operating expenses | ||||
| Research and development expenses | (116.7) | (89.3) | (116.6) | (89.2) |
| Sales and marketing expenses | (3.2) | (2.7) | (3.2) | (2.7) |
| General and administrative expenses | (32.8) | (28.7) | (32.8) | (28.7) |
| Total Operating expenses | (152.7) | (120.7) | (152.6) | (120.6) |
| Loss from operations | (147.1) | (116.6) | (147.0) | (116.5) |
| Financial income (expense) | 0.6 | 2.7 | 0.3 | 2.4 |
| Loss before taxes | (146.5) | (113.8) | (146.6) | (114.1) |
| Income tax | (0.5) | (0.1) | (0.5) | (0.1) |
| Net loss | (147.0) | (113.9) | (147.1) | (114.1) |
| Basic/diluted Net loss per share attributable to shareholders | (1.05) | (1.17) | (1.05) | (1.18) |
About DBV Technologies
DBV Technologies is a late-stage biopharmaceutical company developing treatment options for food allergies and other immunologic conditions with significant unmet medical need. DBV Technologies is currently focused on investigating the use of its proprietary VIASKIN® patch technology to address food allergies, which are caused by a hypersensitive immune reaction and characterized by a range of symptoms varying in severity from mild to life-threatening anaphylaxis. Millions of people live with food allergies, including young children. Through epicutaneous immunotherapy (EPIT), the VIASKIN® patch is designed to introduce microgram amounts of a biologically active compound to the immune system through intact skin. EPIT is a new class of non-invasive treatment that seeks to modify an individual’s underlying allergy by re-educating the immune system to become desensitized to allergen by leveraging the skin’s immune tolerizing properties. DBV Technologies is committed to transforming the care of food allergic people. The Company’s food allergy programs include ongoing clinical trials of the VIASKIN Peanut Patch in peanut allergic toddlers (1 through 3 years of age) and children (4 through 7 years of age).
DBV Technologies is headquartered in Châtillon, France, with North American operations in Warren, NJ. The Company’s ordinary shares are traded on segment B of Euronext Paris (DBV, ISIN code: FR0010417345) and the Company’s ADSs (each representing five ordinary shares) are traded on the Nasdaq Capital Market (DBVT – CUSIP: 23306J309).
For more information, please visit www.dbvtechnologies.com and engage with us on X (formerly Twitter) and LinkedIn.
Forward Looking Statements
This press release contains forward-looking statements, including, without limitation, statements regarding the Company’s financial condition, forecast of its cash runway, the therapeutic potential of Viaskin® patch, designs of DBV’s anticipated clinical trials, DBV’s planned regulatory and clinical efforts including timing and results of communications with regulatory agencies, clinical trial data releases and publications, the potential regulatory submissions, regulatory approval, launch and commercialization of the Company’s product candidates, the ability of any of DBV’s product candidates, if approved, to improve the lives of patients with food allergies, and the Company’s business strategy and goals. These forward-looking statements and estimates are not promises or guarantees and involve substantial risks and uncertainties. At this stage, the Company’s product candidates have not been authorized for sale in any country. Among the factors that could cause actual results to differ materially from those described or projected herein include uncertainties associated generally with research and development, clinical trials and related regulatory reviews and approvals, and the Company’s ability to successfully execute on its budget discipline measures. A further list and description of risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements in this press release can be found in DBV’s regulatory filings with the French Autorité des Marchés Financiers (“AMF”), DBV’s filings and reports with the U.S. Securities and Exchange Commission (“SEC”), including in DBV’s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 26, 2026, and future filings and reports made with the AMF and SEC by DBV. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements and estimates, which speak only as of the date hereof. Other than as required by applicable law, DBV Technologies undertakes no obligation to update or revise the information contained in this Press Release.
VIASKIN is a registered trademark of DBV Technologies.
Investor Contact
Jonathan Neely
DBV Technologies
Jonathan.neely@dbv-technologies.com
Media Contact
Brett Whelan
DBV Technologies
Brett.whelan@dbv-technologies.com
Attachment
FAQ
What did DBVT announce about the VITESSE Phase 3 topline results and timeline?
How much cash did DBVT have at year-end and what is the stated runway?
What financings did DBVT complete in 2025 to fund VIASKIN® Peanut Patch development?
When does DBVT plan BLA submissions for the VIASKIN® Peanut Patch (DBVT)?
How did DBVT's 2025 operating results affect its financials and burn rate?
